Ammonul Injection Warning Issued by FDA

The FDA and Ucyclyd Pharma, Inc., a fully owned subsidiary of Medicis Pharmaceutical Corp., have issued warnings to hospital emergency doctors, nursing personnel and risk managers advising that Ammonul injection products may include particulate matter that could affect the safety of the drug.

The manufacturer recently detected the presence of particulate matter in the Ammonul injection products, which requires healthcare providers to take special steps to ensure the safe use of the drug.

The warning indicates that a Millex Durapore GV 33 mm sterile syringe filter (0.22/lm) should be used in the course of the admixture process, prior to injecting Ammonul into the 10% Dextrose IV bag.

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

Ammonul is a combination of sodium benzoate and sodium phenylacetate, which causes less ammonia to be produced by the body. It is used to treat hyperammonemia, a condition that results from high amounts of ammonia in the blood, which could potentially lead to a brain injury known as encephalopathy, or death.

Ucyclyd Pharma, Inc. warns that the particulate matter may not be readily seen, and the sterile syringe filter should be used in all cases, regardless of whether the particulate matter is seen in the vial.

Particulate matter (PM), referred to as “a mixture of mixtures”, can be solids like soot, ash or dust. It can also take the form of suspended solids in mixtures of liquid or fully liquid aerosols.

Particle pollution causing particulate matter can result in death from cardiovascular causes, including strokes. An increased risk of heart attacks could be caused by particulate matter, especially among the elderly and those with heart problems. Particulate matter has also been associated with increased hospitalization in young children with asthma, inflammation of lung tissue in young and healthy adults, and a higher incidence of asthma attacks in children.

The FDA and drug maker indicate that testing has confirmed that the use of the sterile syringe filter extracted the particulate matter when used before the ad-mix of the Ammonul injection.

In a letter sent to healthcare providers, Ucyclyd indicates that they will distribute Millex Durapore GV 33 mm sterile syringe filters along with all shipments of their Ammonul products as a precautionary measure until further notice.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits
Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits (Posted yesterday)

A federal judge has agreed to divide lawsuits over gastroparesis injuries linked to drugs like Ozempic and Mounjaro into multiple phases, examining how the condition is diagnosed and whether plaintiffs' claims are preempted by federal laws.

Adult Woman Files Similac Lawsuit Over NEC Injuries Experienced as a Newborn
Adult Woman Files Similac Lawsuit Over NEC Injuries Experienced as a Newborn (Posted 2 days ago)

Lawsuit alleges that Abbott Laboratories failed to provide families and the medical community with adequate warnings about the risks associated with it’s cow’s milk-based Similac formula, which a now adult woman indicates has left her with life-long NEC injuries.

Amended Lawsuit Over BioZorb Implant Side Effects Outlines Problems Caused By Tissue Marker Design Defects
Amended Lawsuit Over BioZorb Implant Side Effects Outlines Problems Caused By Tissue Marker Design Defects (Posted 3 days ago)

Six breast cancer patients have asked a federal judge for permission to amend a complaint filed in March 2024, which describes problems linked to the device and painful side effects experienced when the tissue marker migrated out of position or shattered inside their bodies.